Skip to main content
. Author manuscript; available in PMC: 2018 Apr 1.
Published in final edited form as: Cancer Res. 2017 Feb 15;77(7):1719–1729. doi: 10.1158/0008-5472.CAN-16-2159

Figure 5.

Figure 5

Loss of Arid1a and Setd2 provide a selective advantage to tumor progression. Left panels: Percent of tumors that are positive, mixed or negative for a) Brg1, b) Arid1a, or c) H3K36me3 expression as determined by IHC in KrasLSL-G12D/+;p53flox/flox mice at 8, 12, and 16 weeks following tumor initiation. * Animals that succumbed to excessive tumor burden prior to the 16 week time point were included in this analysis. Middle panels: Low magnification H&E image of lobe of lung 16 weeks following tumor initiation in KrasLSL-G12D/+;p53flox/flox mice. Right panels: high magnification H&E image of indicated tumor, inset: IHC for chromatin regulator or histone mark of indicated region of the tumor. Scale bars= 100 µm.